Trevor D. Tenney, Rachel Curtis-Robles, Karen F. Snowden, and Sarah A. Hamer
The protozoan parasite Trypanosoma cruzi is the causative agent of Chagas disease, a neglected tropical disease affecting >8 million persons across Mexico and Central and South America. In the United States, estimates of human infection range from 300,000 to >1 million (1,2). Although immigrants exposed in Chagas disease-endemic regions constitute the majority of infected persons in the United States, autochthonous transmission is increasingly recognized (3), and enzootic cycles involving infected wildlife reservoirs and domestic dogs occur across the southern United States. (4). Vectorborne transmission occurs through contamination of the bite site or mucous membranes with feces of infected hematophagous triatomines (“kissing bugs”). In addition, the parasite can be passed through consumption of infected bugs or contaminated food products, through blood transfusions, and congenitally (4).
Clinical manifestation in humans and dogs ranges from asymptomatic to acute myocarditis and sudden death to chronic progressive cardiac disease (5,6). No vaccine is available for humans or dogs. Drugs used to treat Chagas disease in humans have not been approved by the US Food and Drug Administration and are available in the United States only through investigational protocols. The disease is notifiable in 4 states including Texas, where as of 2013, human and veterinary cases must be reported.
Texas is a high-risk state for transmission of T. cruzi to dogs, considering the diversity of triatomine vectors, reservoir hosts, and previous documentation of canine disease (5,7). Because dogs arriving at shelters may have high exposure to vectors, we expect that shelter dogs will provide a sensitive spatial index of Chagas disease risk across the landscape. The objective of this study was to measure T. cruzi seroprevalence in shelter dog populations across Texas.
The Study
Figure
Figure. Locations of canine shelters within Texas, United States, 2013Shelters (A–G) are distributed across 7 of the 10 Gould Ecoregions of Texas (9), Map obtained from Texas parks and Wildlife...
To assess exposure to T. cruzi, we established a network of 7 canine shelters in major cities and rural areas representing diverse ecoregions across Texas (8; Figure). Using a cross-sectional study design, we collected blood samples during May–August 2013 from ≤30 dogs at each shelter, in adherence with client-owned animal use protocols approved by Texas A&M University Institutional Animal Care and Use Committee. Enrollment criteria for our study included dogs >6 months of age within 4 days of admittance to shelters. We detected exposure to T. cruzi using Chagas STAT-PAK, a commercially available rapid immunochromatographic test (Chembio Diagnostic Systems, Inc., Medford, NY, USA) that has been validated for use in dogs (9) and has high sensitivity and specificity when compared with conventional serologic techniques (10). To detect parasite DNA within blood, we followed this process: a 200-μL aliquot of centrifuged blood, including the buffy coat, from a subset of seropositive and seronegative dogs across all shelters was subjected to DNA extraction and used as the template in a real-time quantitative PCR with a TaqMan probe to amplify a 166-bp repetitive sequence of satellite DNA specific to T. cruzi (11). Using a sequential testing approach, we subjected positive samples in the real-time quantitative PCR to a second confirmatory PCR using previously published TCZ primers to amplify a 188-bp sequence of satellite DNA (12). Samples positive by both assays were considered to contain T. cruzi DNA within the blood.
A total of 205 blood samples were collected from shelter dogs. Dogs enrolled in the study ranged from 6 months to 13 years of age and represented diverse breed groups. A total of 18 (8.8%) dogs were seropositive for T. cruzi antibodies. Seropositive dogs were found at all shelters within the network; shelter prevalence ranged from 6.7% to 13.8% (Table). Using logistic regression, we found no differences in the odds of seropositivity across location, sex, age category, breed group, and dog origin (Table). In a subset of 50 dogs, including 14 seropositive and 36 seronegative dogs, 3 (6%) blood samples were positive for T. cruzi DNA by both PCR methods, each with similar cycle threshold values indicative of ≈50 parasite equivalents of DNA per mL of blood. PCR-positive dogs included 2 male and 1 female dog of sporting and toy breeds from shelters A, C, and F, ranging in age from 1.5 to 7 years. Of these 3 dogs, 1 was serologically positive for antibodies against T. cruzi.
Additionally, we observed very faint-colored bands on serologic dipsticks in samples from 26 dogs that are not included in the overall seroprevalence estimate. Because we were uncertain of how to interpret antibody presence in these samples, we submitted a subset (n = 11) for indirect fluorescent antibody testing at the Texas Veterinary Medical Diagnostic Laboratory, of which 4 samples (36.3%) tested positive. Although cross-reactivity cannot be ruled out by using the indirect fluorescent antibody technique, these data suggest that the seroprevalence we report (8.8%) is a conservative estimate.
Conclusions
Shelter dogs had widespread exposure to T. cruzi across 7 ecologic regions in Texas, with a conservative statewide average of 8.8% seroprevalence. The presence of seropositive dogs across all sampled regions, age classes, breed groups, and canine origins suggests that ecologic requirements for parasite transmission to dogs are not constrained to focal areas or particular breed groups. Although the travel histories of dogs in our study are unknown, the presence of antibodies in dogs across all age classes, including young dogs that are less likely to have traveled, suggests local exposure. Furthermore, at least some shelters are located in regions in which kissing bugs have previously been reported (7). The only published prospective seroprevalence study of dogs from 1 county in south Texas reported a seroprevalence of 7.5% (n = 375 stray dogs) (13), similar to our statewide average. Across 2 regions in Mexico, including 1 where Chagas disease was previously considered nonendemic, seroprevalence of T. cruzi in canines ranged from 17.5% to 21% and was directly correlated with T. cruzi seroprevalence in humans in these regions (14). Further research is needed to quantify the association between infection of canines with T. cruzi and risk for Chagas disease among humans in the United States.
The widely accepted concept of Chagas disease is that T. cruzi infection is lifelong, which is supported by continuous detection of antibody presence within hosts. Despite detection of antibodies in dogs sampled across the state, parasite DNA was detected in the blood of only 3 dogs. Limited experimental investigations of T. cruzi infection of dogs indicate that parasitemia is detectable cytologically as soon as 3 days after inoculation and lasts <3 weeks (5), after which the parasite localizes in tissues and parasitemia is undetectable. Our observations suggest that most seropositive dogs were not in the acute phase of the infection at the time of sampling. Although domestic dogs have been shown to serve as reservoir hosts in some regions of Central and South America (15), the importance of dogs relative to wildlife hosts as reservoirs in the United States is unknown.
Dogs that arrive at shelters, especially stray dogs, are likely to have had increased exposure to the outdoors and vectors and have been shown to have higher exposure to vectorborne pathogens than client-owned dogs that are brought to veterinary clinics (16). Shelter dogs, therefore, provide a sensitive population for assessment of local canine transmission risk, and we suggest that awareness of kissing bugs and Chagas disease risk among citizens and the medical community should be heightened in areas where seropositive dogs are detected.
Mr Tenney is a second-year veterinary student at Texas A&M University in College Station, Texas. His research interests include military veterinary medicine and infectious diseases.
Top
Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009;49:e52–4. DOIPubMedGoogle Scholar
Hanford EJ, Zhan FB, Lu YM, Giordano A. Chagas disease in Texas: recognizing the significance and implications of evidence in the literature. Soc Sci Med. 2007;65:60–79. DOIPubMedGoogle Scholar
Cantey PT, Stramer SL, Townsend RL, Kamel H, Ofafa K, Todd CW, The United States Trypanosoma cruzi infection study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion. 2012;52:1922–30. DOIPubMedGoogle Scholar
Bern C, Kjos S, Yabsley MJ, Montgomery SP. Trypanosoma cruzi and Chagas’ disease in the United States. Clin Microbiol Rev. 2011;24:655–81. DOIPubMedGoogle Scholar
Barr SC. Canine Chagas' disease (American Trypanosomiasis) in North America. Vet Clin N Am-Small. 2009 Nov;39(6):1055–64.
Rassi A, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375:1388–402. DOIPubMedGoogle Scholar
Kjos SA, Snowden KF, Olson JK. Biogeography and Trypanosoma cruzi infection prevalence of Chagas disease vectors in Texas, USA. Vector Borne Zoonotic Dis. 2009;9:41–50 . DOIPubMedGoogle Scholar
Gould FW, Hoffman GO, Rechenthin CA. Vegetational areas of Texas; 1960. Texas Agricultural Experiment Station, Texas A&M University (Texas). Leaflet no. 492. http://aggieclover.tamu.edu/map/
Nieto PD, Boughton R, Dorn PL, Steurer F, Raychaudhuri S, Esfandiari J, Comparison of two immunochromatographic assays and the indirect immunofluorescence antibody test for diagnosis of Trypanosoma cruzi infection in dogs in south central Louisiana. Vet Parasitol. 2009;165:241–7. DOIPubMedGoogle Scholar
Luquetti AO, Ponce C, Ponce E, Esfandiari J, Schijman A, Revollo S, Chagas’ disease diagnosis: a multicentric evaluation of Chagas Stat-Pak, a rapid immunochromatographic assay with recombinant proteins of Trypanosoma cruzi. Diagn Microbiol Infect Dis. 2003;46:265–71. DOIPubMedGoogle Scholar
Duffy T, Cura CI, Ramirez JC, Abate T, Cayo NM, Parrado R, Analytical performance of a multiplex real-time PCR assay using TaqMan probes for quantification of Trypanosoma cruzi satellite DNA in blood samples. PLoS Negl Trop Dis. 2013;7:•••. DOIPubMedGoogle Scholar
Virreira M, Torrico F, Truyens C, Alonso-Vega C, Solano M, Carlier Y, Comparison of polymerase chain reaction methods for reliable and easy detection of congenital Trypanosoma cruzi infection. Am J Trop Med Hyg. 2003;68:574–82 .PubMedGoogle Scholar
Beard CB, Pye G, Steurer FJ, Rodriguez R, Campman R, Peterson AT, Chagas disease in a domestic transmission cycle, southern Texas, USA. Emerg Infect Dis. 2003;9:103–5. DOIPubMedGoogle Scholar
Estrada-Franco JG, Bhatia V, Diaz-Albiter H, Ochoa-Garcia L, Barbabosa A, Vazquez-Chagoyan JC, Human Trypanosoma cruzi infection and seropositivity in dogs, Mexico. Emerg Infect Dis. 2006;12:624–30. DOIPubMedGoogle Scholar
Ramírez JD, Turriago B, Tapia-Calle G, Guhl F. Understanding the role of dogs (Canis lupus familiaris) in the transmission dynamics of Trypanosoma cruzi genotypes in Colombia. Vet Parasitol. 2013;196:216–9. DOIPubMedGoogle Scholar
Amusategui I, Tesouro MA, Kakoma I, Sainz A. Serological reactivity to Ehrlichia canis, Anaplasma phagocytophilum, Neorickettsia risticii, Borrelia burgdorferi and Rickettsia conorii in dogs from northwestern Spain. Vector Borne Zoonotic Dis. 2008;8:797–804. DOIPubMedGoogle Scholar